ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 107,66
-1,08%
Dow Jones
39 806,77
0,00%
DAX
18 659,68
-0,57%
Brent Oil
82,305
-1,47%
Bitcoin
71 302,36
-0,21%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Aprea Therapeutics Inc (APRE)

  7. Aprea Therapeutics Inc (APRE) Actualités

APRE

Aprea Therapeutics (APRE)

Aprea Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:APRE
DateHeureSourceTitreSymboleSociété
14/05/202414h40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APREAprea Therapeutics Inc
14/05/202414h35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APREAprea Therapeutics Inc
05/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APREAprea Therapeutics Inc
26/01/202412h03Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:APREAprea Therapeutics Inc
09/11/202322h20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APREAprea Therapeutics Inc
25/08/202303h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APREAprea Therapeutics Inc
11/07/202313h40Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:APREAprea Therapeutics Inc
11/07/202313h30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:APREAprea Therapeutics Inc
14/06/202314h00GlobeNewswire Inc.Aprea Therapeutics to Present at Maxim Virtual Healthcare ConferenceNASDAQ:APREAprea Therapeutics Inc
08/06/202322h35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:APREAprea Therapeutics Inc
30/05/202314h30GlobeNewswire Inc.Aprea Therapeutics to Present at BIO International ConventionNASDAQ:APREAprea Therapeutics Inc
15/05/202322h48Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:APREAprea Therapeutics Inc
15/05/202322h40Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:APREAprea Therapeutics Inc
15/05/202322h05GlobeNewswire Inc.Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business OperationsNASDAQ:APREAprea Therapeutics Inc
08/05/202323h16Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:APREAprea Therapeutics Inc
08/05/202314h00GlobeNewswire Inc.Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of DirectorsNASDAQ:APREAprea Therapeutics Inc
30/03/202323h02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:APREAprea Therapeutics Inc
30/03/202322h05GlobeNewswire Inc.Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business OperationsNASDAQ:APREAprea Therapeutics Inc
16/03/202313h00GlobeNewswire Inc.Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual MeetingNASDAQ:APREAprea Therapeutics Inc
07/03/202314h00GlobeNewswire Inc.Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare ConferenceNASDAQ:APREAprea Therapeutics Inc
03/03/202312h06Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:APREAprea Therapeutics Inc
01/03/202322h05GlobeNewswire Inc.Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:APREAprea Therapeutics Inc
27/02/202322h05GlobeNewswire Inc.Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common StockNASDAQ:APREAprea Therapeutics Inc
24/02/202323h24Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:APREAprea Therapeutics Inc
23/02/202302h41GlobeNewswire Inc.Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common StockNASDAQ:APREAprea Therapeutics Inc
22/02/202322h05GlobeNewswire Inc.Aprea Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:APREAprea Therapeutics Inc
15/02/202314h00GlobeNewswire Inc.Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)NASDAQ:APREAprea Therapeutics Inc
13/02/202313h00GlobeNewswire Inc.Aprea Therapeutics Announces One-for-Twenty Reverse Stock SplitNASDAQ:APREAprea Therapeutics Inc
30/01/202314h00GlobeNewswire Inc.Aprea Therapeutics Appoints John Hamill as Chief Financial OfficerNASDAQ:APREAprea Therapeutics Inc
19/01/202314h00GlobeNewswire Inc.Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors SummitNASDAQ:APREAprea Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:APRE

Dernières Valeurs Consultées

EU
GLE
Societe Generale
EU
LR
Legrand
EU
AI
Air Liquide
EU
PX4
SBF 120
EU
VK
Vallourec
EU
BNP
BNP Paribas
COIN
ETHUSD
Ethereum
EU
VIV
Vivendi
EU
RNO
Renault
FTSE
UKX
FTSE 100
NYSE
MCD
McDonalds
NYSE
DIS
Walt Disney
EU
AF
Air FranceKLM
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés